Official Journal of the European Union

C 29

English edition

Information and Notices

Volume 65

20 January 2022

Contents

IV *Notices*

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2022/C 29/01 Administrative Commission for the Coordination of Social Security Systems Average costs of benefits in kind 1

2022/C 29/02 Commission notice on current State aid recovery interest rates and reference/discount rates applicable as from 1 February 2022 *(Published in accordance with Article 10 of Commission Regulation (EC) No 794/2004)* 3

2022/C 29/03 Explanatory Notes to the Combined Nomenclature of the European Union 4

NOTICES CONCERNING THE EUROPEAN ECONOMIC AREA

Standing Committee of the EFTA States

2022/C 29/04 Medicinal products - List of marketing authorisations granted by the EEA EFTA States for the first half of 2021 7

2022/C 29/05 Dangerous substances – List of authorisation decisions taken by the EEA EFTA States in accordance with Article 44(5) of Regulation (EU) 528/2012 in the first half of 2021 30

2022/C 29/06 Dangerous substances – List of authorisation decisions taken by the EEA EFTA States in accordance with Article 64(8) of Regulation (EC) 1907/2006 (REACH) in the first half of 2021 32

EN

V *Announcements*

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMMON COMMERCIAL POLICY

European Commission

2022/C 29/07 Notice of initiation of an expiry review of the anti-dumping measures applicable to imports of certain aluminium road wheels originating in the People's Republic of China 34

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

2022/C 29/08 Prior notification of a concentration (Case M.10564 – APOLLO / MISSGUIDED) – Candidate case for simplified procedure ([1]) 46

([1]) Text with EEA relevance.

IV

(Notices)

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

EUROPEAN COMMISSION

ADMINISTRATIVE COMMISSION FOR THE COORDINATION OF SOCIAL SECURITY SYSTEMS AVERAGE COSTS OF BENEFITS IN KIND

(2022/C 29/01)

AVERAGE COSTS OF BENEFITS IN KIND – 2019

Application of Article 64 of Regulation (EC) No 987/2009 ([1])

I. The amounts to be refunded with regard to the benefits in kind provided in 2019 to family members who do not reside in the same State as the insured person, as referred to in Article 17 of Regulation (EC) No 883/2004 ([2]), will be determined on the basis of the following average costs:

	Age group	Annual	Net monthly x=0,20
Cyprus	under 20 years	EUR 515,87	EUR 34,39
	20 - 64 years	EUR 566,67	EUR 37,78
	65 years and over	EUR 2 228,83	EUR 148,59

II. The amounts to be refunded with regard to benefits in kind provided in 2019 to pensioners and members of their family, as provided for in Article 24(1) and Articles 25 and 26 of Regulation (EC) No 883/2004, will be determined on the basis of the following average costs:

	Age group	Annual	Net monthly x=0,20	Net monthly x=0,15 ([1])
Cyprus	under 20 years	EUR 515,87	EUR 34,39	EUR 36,54
	20 – 64 years	EUR 566,67	EUR 37,78	EUR 40,14
	65 years and over	EUR 2 228,83	EUR 148,59	EUR 157,88

([1]) The reduction applied to the monthly fixed amount 'shall be equal to 15 % (X = 0,15) for pensioners and members of their family where the competent Member State is not listed in Annex IV of the basic Regulation' (Article 64(3) of Regulation (EC) No 987/2009).

([1]) OJ L 284, 30.10.2009, p. 1.
([2]) OJ L 166, 30.4.2004, p. 1.

AVERAGE COSTS OF BENEFITS IN KIND – 2020

Application of Article 64 of Regulation (EC) No 987/2009

I. The amounts to be refunded with regard to the benefits in kind provided in 2020 to family members who do not reside in the same State as the insured person, as referred to in Article 17 of Regulation (EC) No 883/2004, will be determined on the basis of the following average costs:

	Age group	Annual	Net monthly x=0,20
Spain	under 20 years	EUR 664,68	EUR 44,31
	20 - 64 years	EUR 1 000,19	EUR 66,68
	65 years and over	EUR 5 114,42	EUR 340,96

II. The amounts to be refunded with regard to benefits in kind provided in 2020 to pensioners and members of their family, as provided for in Article 24(1) and Articles 25 and 26 of Regulation (EC) No 883/2004, will be determined on the basis of the following average costs:

	Age group	Annual	Net monthly x=0,20	Net monthly x=0,15 ([1])
Spain	under 20 years	EUR 664,68	EUR 44,31	EUR 47,08
	20 – 64 years	EUR 1 000,19	EUR 66,68	EUR 70,85
	65 years and over	EUR 5 114,42	EUR 340,96	EUR 362,27

([1]) The reduction applied to the monthly fixed amount 'shall be equal to 15 % (X = 0,15) for pensioners and members of their family where the competent Member State is not listed in Annex IV of the basic Regulation' (Article 64(3) of Regulation (EC) No 987/2009).

Commission notice on current State aid recovery interest rates and reference/discount rates applicable as from 1 February 2022

(Published in accordance with Article 10 of Commission Regulation (EC) No 794/2004 [1]*)*

(2022/C 29/02)

Base rates calculated in accordance with the Communication from the Commission on the revision of the method for setting the reference and discount rates (OJ C 14, 19.1.2008, p. 6.). Depending on the use of the reference rate, the appropriate margins have still to be added as defined in this communication. For the discount rate this means that a margin of 100 basispoints has to be added. The Commission Regulation (EC) No 271/2008 of 30 January 2008 amending Regulation (EC) No 794/2004 foresees that, unless otherwise provided for in a specific decision, the recovery rate will also be calculated by adding 100 basispoints to the base rate.

Modified rates are indicated in bold.

Previous table published in OJ C 504, 14.12.2021, p. 47.

From	To	AT	BE	BG	CY	CZ	DE	DK	EE	EL	ES	FI	FR	HR	HU	IE	IT	LT	LU	LV	MT	NL	PL	PT	RO	SE	SI	SK	UK
1.2.2022	…	- 0,49	- 0,49	0,00	- 0,49	**3,29**	- 0,49	**- 0,03**	- 0,49	- 0,49	- 0,49	- 0,49	- 0,49	0,26	**3,17**	- 0,49	- 0,49	- 0,49	- 0,49	- 0,49	- 0,49	- 0,49	**2,04**	- 0,49	**2,74**	**- 0,05**	- 0,49	- 0,49	**0,66**
1.1.2022	31.1.2022	**- 0,49**	**- 0,49**	**0,00**	**- 0,49**	**2,49**	**- 0,49**	**- 0,01**	**- 0,49**	**- 0,49**	**- 0,49**	**- 0,49**	**- 0,49**	**0,26**	**2,38**	**- 0,49**	**- 0,49**	**- 0,49**	**- 0,49**	**- 0,49**	**- 0,49**	**- 0,49**	**1,21**	**- 0,49**	**2,27**	**- 0,03**	**- 0,49**	**- 0,49**	**0,51**

[1] OJ L 140, 30.4.2004, p. 1.

Explanatory Notes to the Combined Nomenclature of the European Union

(2022/C 29/03)

Pursuant to Article 9(1)(a) of Council Regulation (EEC) No 2658/87 ([1]), the Explanatory Notes to the Combined Nomenclature of the European Union ([2]) are hereby amended as follows:

On page 412, the following explanatory note is inserted:

'**9503 00 41 Stuffed**

Stuffed toys of this subheading usually have an outer fabric of a soft material and are usually filled with flexible/soft material that makes the toy pleasant to hold. Musical modules, battery housings or skeletons are not considered as stuffing material. A stuffed toy does not require to be fully stuffed as long as the stuffed parts give the toy the essential character of a stuffed toy.
See Commission Implementing Regulation (EU) 2015/352(*) and Commission Regulation (EC) No 2184/97(**) for toys that are to be classified in subheading 9503 00 41.

(*) Commission Implementing Regulation (EU) 2015/352 of 2 March 2015 concerning the classification of certain goods in the Combined Nomenclature (OJ L 61, 5.3.2015, p. 5).
(**) Commission Regulation (EC) No 2184/97 of 3 November 1997 concerning the classification of certain goods in the combined nomenclature (OJ L 299, 4.11.1997, p. 6).

Other examples of toys that are to be classified in subheading 9503 00 41 as stuffed toys representing animals or non-human creatures:

Stuffed toy representing a bear made of soft fabric, approximately 30 cm high, with a relatively big stuffed head, stuffed legs and stuffed arms and a built-in sound module in the body. Besides the sound module, there is also slight stuffing in the body.

([1]) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (OJ L 256, 7.9.1987, p. 1).
([2]) OJ C 119, 29.3.2019, p. 1.

Little singing teddy bear with interactive features, approximately 19 cm high.
The body is made out of plastic, it incorporates a battery powered sound module and it has 3 light-up pressing buttons.
It has a stuffed head, stuffed legs, stuffed feet, stuffed arms and hands. The stuffed parts taken together constitute the prevailing part of the interior material filling.

A toy representing a stuffed horse's head attached to a wooden stick (60 to 100 cm long) with two wheels attached at the bottom.
Examples of toys that are to be classified in subheading 9503 00 49 as other toys representing animals or non-human creatures:

A toy representing a dog, approximately 25 cm high, covered with soft knitted plush fabric. It has a body and a skeleton of plastics fitted with a battery-powered motor and a sound module. The four paws have a layer of lining attached at the inner side and the head is stuffed.



A toy representing a lama, approximately 17 cm high, covered with soft plush fabric. The body, the head and the skeleton are made of plastics. There is a layer of padding between the plastic head and the soft plush fabric covering the head, but the body does not contain any stuffed material. The toy has a battery-powered motor, which allows the toy to move the legs and the tail, and a sound module.

A toy representing a kitten, approximately 15 cm high, covered with soft knitted plush fabric. It has a body and a skeleton of plastics fitted with a battery-powered motor and a sound module. The four paws are stuffed.

A toy representing a rescue dog, approximately 30 cm high, covered with soft knitted plush fabric. It has a body and skeleton of plastics fitted with a battery-powered motor and a sound module. The four paws and a part of the muzzle are stuffed.'

NOTICES CONCERNING THE EUROPEAN ECONOMIC AREA

STANDING COMMITTEE OF THE EFTA STATES

Medicinal products - List of marketing authorisations granted by the EEA EFTA States for the first half of 2021

(2022/C 29/04)

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January – 30 June 2021, at their meeting on 24 September 2021:

Annex I	List of new marketing authorisations
Annex II	List of renewed marketing authorisations
Annex III	List of extended marketing authorisations
Annex IV	List of withdrawn marketing authorisations
Annex V	List of suspended marketing authorisations

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January – 30 June 2021:

EU-Number	Product	Country	Date of authorisation
EU/1/20/1515	Abevmy	Iceland	12.5.2021
EU/1/20/1515	Abevmy	Liechtenstein	30.4.2021
EU/1/20/1515	Abevmy	Norway	28.4.2021
EU/1/20/1512	Abirateron Accord	Liechtenstein	30.4.2021
EU/1/20/1512	Abiraterone Accord	Iceland	14.5.2021
EU/1/20/1512	Abiraterone Accord	Norway	6.5.2021
EU/1/21/1553	Abiraterone Krka	Liechtenstein	30.6.2021
EU/1/21/1553	Abiraterone Krka	Norway	30.6.2021
EU/1/20/1476	Adakveo (conditional)	Liechtenstein	15.1.2021
EU/1/21/1554	Adtralza	Liechtenstein	30.6.2021
EU/1/21/1554	Adtralza	Norway	22.6.2021
EU/1/20/1509	Alymsys	Iceland	14.4.2021
EU/1/20/1509	Alymsys	Liechtenstein	30.4.2021
EU/1/20/1509	Alymsys	Norway	8.4.2021
EU/1/20/1469	Arikayce liposomal	Liechtenstein	15.1.2021
EU/1/20/1475	Arsenic trioxide medac	Liechtenstein	28.2.2021
EU/2/18/228	Arti-Cell Forte	Liechtenstein	28.2.2021
EU/1/20/1473	Ayvakyt	Liechtenstein	28.2.2021
EU/1/18/1339	Bevespi Aerosphere	Liechtenstein	28.2.2021
EU/2/99/017	Bovalto Ibraxion	Liechtenstein	28.2.2021
EU/1/21/1534	BroPair Spiromax	Iceland	14.4.2021
EU/1/21/1534	BroPair Spiromax	Liechtenstein	30.4.2021
EU/1/21/1534	BroPair Spiromax	Norway	8.4.2021
EU/2/10/112	BTVPUR AlSap 1	Liechtenstein	28.2.2021
EU/2/09/094	BTVPUR AlSap 8	Liechtenstein	28.2.2021
EU/1/20/1505	Byfavo	Iceland	26.4.2021
EU/1/20/1505	Byfavo	Norway	8.4.2021

EU-Number	Product	Country	Date of authorisation
EU/1/20/1505	Byvafo	Liechtenstein	30.4.2021
EU/120/1448	Cabazitaxel Accord	Liechtenstein	28.2.2021
EU/1/20/1479	Calquence	Liechtenstein	15.1.2021
EU/1/21/1560	Celsunax	Liechtenstein	30.6.2021
EU/1/21/1560	Celsunax	Norway	23.6.2021
EU/2/20/264	CircoMax Myco	Iceland	4.1.2021
EU/2/20/264	CircoMax Myco	Liechtenstein	15.1.2021
EU/1/19/1395	Clopidogrel/Acetylsalicylic acid Mylan	Liechtenstein	28.2.2021
EU/1/20/1528	Comirnaty (conditional)	Liechtenstein	15.1.2021
EU/1/21/1542	Copiktra	Iceland	9.6.2021
EU/1/21/1542	Copiktra	Liechtenstein	30.6.2021
EU/1/21/1542	Copiktra	Norway	3.6.2021
EU/2/18/230	Cortacare	Liechtenstein	28.2.2021
EU/1/21/1529	COVID-19 Vaccine AstraZeneca	Iceland	29.1.2021
EU/1/21/1529	COVID-19 Vaccine AstraZeneca	Liechtenstein	28.2.2021
EU/1/20/1529	COVID-19 Vaccine AstraZeneca (Vaxzevria)	Norway	29.1.2021
EU/1/20/1525	COVID-19 Vaccine Janssen	Iceland	11.3.2021
EU/1/20/1525	COVID-19 Vaccine Janssen	Liechtenstein	30.4.2021
EU/1/20/1525	COVID-19 Vaccine Janssen	Norway	11.3.2021
EU/1/20/1507	COVID-19 Vaccine Moderna	Iceland	6.1.2021
EU/1/20/1507	COVID-19 Vaccine Moderna (conditional)	Liechtenstein	15.1.2021
EU/1/20/1507	COVID-19 Vaccine Moderna (Spikevax)	Norway	6.1.2021
EU/2/21/271	Credelio Plus	Iceland	26.4.2021
EU/2/21/271	Credelio Plus	Liechtenstein	30.4.2021
EU/2/21/271	Credelio Plus	Norway	19.4.2021
EU/1/17/1248	Darunavir Krka d.d.	Liechtenstein	28.2.2021

EU-Number	Product	Country	Date of authorisation
EU/2/21/270	Daxocox	Iceland	14.5.2021
EU/2/21/270	Daxocox	Liechtenstein	30.4.2021
EU/2/21/270	Daxocox	Norway	3.6.2021
EU/1/19/1412	Deferasirox Accord	Liechtenstein	28.2.2021
EU/1/21/1547	Drovelis	Iceland	8.6.2021
EU/1/21/1547	Drovelis	Liechtenstein	30.6.2021
EU/1/21/1547	Drovelis	Norway	3.6.2021
EU/1/18/1284	Dzuveo	Liechtenstein	28.2.2021
EU/1/21/1549	Efmody	Iceland	10.6.2021
EU/1/21/1549	Efmody	Liechtenstein	30.4.2021
EU/1/21/1549	Efmody	Norway	10.6.2021
EU/1/20/1504	Elzonris	Iceland	19.1.2021
EU/1/20/1504	Elzonris	Liechtenstein	28.2.2021
EU/1/20/1504	Elzonris	Norway	18.1.2021
EU/1/18/1330	Emgality	Liechtenstein	28.2.2021
EU/1/20/1438	Enerzair Breezhaler	Liechtenstein	28.2.2021
EU/1/20/1508	Enhertu	Iceland	28.1.2021
EU/1/20/1508	Enhertu	Liechtenstein	28.2.2021
EU/1/20/1508	Enhertu	Norway	26.1.2021
EU/1/21/1559	Enspryng	Liechtenstein	30.6.2021
EU/2/20/268	Enteroporc Coli	Iceland	21.1.2021
EU/2/20/268	Enteroporc Coli	Liechtenstein	15.1.2021
EU/2/20/268	Enteroporc Coli	Norway	3.6.2021
EU/2/20/262	Enteroporc Coli AC	Iceland	8.1.2021
EU/2/20/262	Enteroporc Coli AC	Liechtenstein	15.1.2021
EU/1/20/1472	Equidacent	Liechtenstein	15.1.2021
EU/1/19/1392	Ervebo	Liechtenstein	28.2.2021
EU/1/12/750	Esmya	Iceland	1.2.2021
EU/1/21/1551	Evkeeza	Liechtenstein	30.6.2021
EU/1/21/1551	Evkeeza	Norway	30.6.2021
EU/1/21/1531	Evrysdi	Iceland	14.4.2021

EU-Number	Product	Country	Date of authorisation
EU/1/21/1531	Evrysdi	Liechtenstein	30.4.2021
EU/1/21/1531	Evrysdi	Norway	8.4.2021
EU/1/20/1489	Exparel liposomal	Liechtenstein	28.2.2021
EU/1/20/1477	Fampridine Accord	Liechtenstein	15.1.2021
EU/1/20/1491	Fintepla	Iceland	22.1.2021
EU/1/20/1491	Fintepla	Liechtenstein	15.1.2021
EU/1/20/1491	Fintepla	Norway	15.1.2021
EU/1/18/1326	Flucelvax Tetra	Liechtenstein	28.2.2021
EU/1/19/1375	Grasustek	Liechtenstein	28.2.2021
EU/1/20/1503	Heplisav B	Iceland	22.2.2021
EU/1/20/1503	Heplisav B	Liechtenstein	28.2.2021
EU/1/20/1503	Heplisav B	Norway	25.2.2021
EU/2/20/258	Increxxa	Liechtenstein	28.2.2021
EU/2/20/258	Increxxa	Norway	22.2.2021
EU/2/17/208	Ingelvac PCV FLEX	Liechtenstein	28.2.2021
EU/2/17/213	Innovax-ND-IBD	Liechtenstein	28.2.2021
EU/2/20/256	Innovax-ND-ILT	Liechtenstein	15.1.2021
EU/2/20/256	Innovax-ND-ILT	Norway	4.1.2021
EU/1/20/1514	Inrebic	Iceland	19.2.2021
EU/1/20/1514	Inrebic	Liechtenstein	28.2.2021
EU/1/20/1514	Inrebic	Norway	11.2.2021
EU/2/18/232	Isemid	Liechtenstein	28.2.2021
EU/1/19/1396	Ivozall	Liechtenstein	28.2.2021
EU/1/21/1557	Jayempi	Liechtenstein	30.6.2021
EU/1/21/1557	Jayempi	Norway	30.6.2021
EU/1/21/1538	Jemperli	Iceland	12.5.2021
EU/1/21/1538	Jemperli	Liechtenstein	30.4.2021
EU/1/21/1538	Jemperli	Norway	28.4.2021
EU/1/20/1480	Jyseleca	Liechtenstein	15.1.2021
EU/1/21/1532	Kesimpta	Iceland	15.4.2021
EU/1/21/1532	Kesimpta	Liechtenstein	30.4.2021
EU/1/21/1532	Kesimpta	Norway	8.4.2021
EU/1/20/1506	Kixelle	Iceland	18.2.2021

EU-Number	Product	Country	Date of authorisation
EU/1/20/1506	Kixelle	Liechtenstein	28.2.2021
EU/1/20/1506	Kixelle	Norway	11.2.2021
EU/1/21/1552	Koselugo	Liechtenstein	30.6.2021
EU/1/21/1552	Koselugo	Norway	22.6.2021
EU/1/20/1520	Lenalidomide Krka	Iceland	4.3.2021
EU/1/20/1520	Lenalidomide Krka	Liechtenstein	28.2.2021
EU/1/20/1520	Lenalidomide Krka	Norway	21.6.2021
EU/1/20/1521	Lenalidomide Krka d.d.	Iceland	5.3.2021
EU/1/20/1521	Lenalidomide Krka d.d.	Liechtenstein	30.4.2021
EU/1/20/1521	Lenalidomide Krka d.d.	Norway	16.6.2021
EU/1/20/1519	Lenalidomide Krka d.d. Novo mesto	Iceland	24.2.2021
EU/1/20/1519	Lenalidomide Krka d.d. Novo mesto	Liechtenstein	28.2.2021
EU/1/20/1519	Lenalidomide Krka d.d. Novo mesto	Norway	18.6.2021
EU/1/20/1490	Lenalidomide Mylan	Iceland	11.1.2021
EU/1/20/1490	Lenalidomide Mylan	Liechtenstein	28.2.2021
EU/1/20/1494	Leqvio	Iceland	5.1.2021
EU/1/20/1494	Leqvio	Liechtenstein	15.1.2021
EU/1/20/1516	Lextemy	Iceland	12.5.2021
EU/1/20/1516	Lextemy	Liechtenstein	30.4.2021
EU/1/20/1516	Lextemy	Norway	28.4.2021
EU/1/20/1493	Libmeldy	Iceland	14.1.2021
EU/1/20/1493	Libmeldy	Liechtenstein	15.1.2021
EU/1/20/1493	Libmeldy	Norway	8.1.2021
EU/2/20/261	Librela	Liechtenstein	15.1.2021
EU/2/20/261	Librela	Norway	4.1.2021
EU/1/20/1470	Lumeblue	Liechtenstein	28.2.2021
EU/1/20/1522	Lumoxiti	Iceland	19.2.2021
EU/1/20/1522	Lumoxiti	Liechtenstein	28.2.2021
EU/1/20/1522	Lumoxiti	Norway	11.2.2021

EU-Number	Product	Country	Date of authorisation
EU/1/21/1548	Lydisilka	Iceland	8.6.2021
EU/1/21/1548	Lydisilka	Liechtenstein	30.6.2021
EU/1/21/1548	Lydisilka	Norway	31.5.2021
EU/1/20/1483	MenQuadfi	Liechtenstein	15.1.2021
EU/2/20/259	Mhyosphere PCV ID	Liechtenstein	28.2.2021
EU/2/20/259	Mhyosphere PCV ID	Norway	4.1.2021
EU/1/20/1445	Mvabea	Liechtenstein	28.2.2021
EU/1/18/1325	Namuscla	Liechtenstein	28.2.2021
EU/2/20/267	NexGard Combo	Iceland	25.1.2021
EU/2/20/267	NexGard Combo	Liechtenstein	28.2.2021
EU/2/20/267	NexGard Combo	Norway	20.1.2021
EU/1/21/1537	Nexpovio	Iceland	30.3.2021
EU/1/21/1537	Nexpovio	Liechtenstein	30.4.2021
EU/1/21/1537	Nexpovio	Norway	8.4.2021
EU/1/18/1290	Nityr	Liechtenstein	28.2.2021
EU/2/20/265	Nobivac DP Plus	Iceland	4.1.2021
EU/2/20/265	Nobivac DP Plus	Liechtenstein	15.1.2021
EU/1/19/1364	Nuceiva	Liechtenstein	28.2.2021
EU/1/20/1486	Nyvepria	Liechtenstein	15.1.2021
EU/1/20/1485	Obiltoxaximab SFL (exceptional circumstances)	Liechtenstein	15.1.2021
EU/1/20/1523	Ogluo	Iceland	22.2.2021
EU/1/20/1523	Ogluo	Liechtenstein	28.2.2021
EU/1/20/1523	Ogluo	Norway	23.2.2021
EU/1/20/1499	Onbevzi	Iceland	19.1.2021
EU/1/20/1499	Onbevzi	Liechtenstein	28.2.2021
EU/1/20/1499	Onbevzi	Norway	15.1.2021
EU/1/21/1530	Ontozry	Iceland	15.4.2021
EU/1/21/1530	Ontozry	Liechtenstein	30.4.2021
EU/1/21/1530	Ontozry	Norway	9.4.2021
EU/1/21/1556	Onureg	Liechtenstein	30.6.2021
EU/1/21/1556	Onureg	Norway	22.6.2021
EU/1/21/1544	Orladeyo	Iceland	14.5.2021

EU-Number	Product	Country	Date of authorisation
EU/1/21/1544	Orladeyo	Liechtenstein	30.6.2021
EU/1/21/1544	Orladeyo	Norway	6.5.2021
EU2/20/260	OvuGel	Liechtenstein	28.2.2021
EU/2/20/260	OvuGel	Norway	4.1.2021
EU/1/20/1496	Oxlumo	Liechtenstein	15.1.2021
EU/1/20/1510	Oyavas	Iceland	14.4.2021
EU/1/20/1510	Oyavas	Liechtenstein	30.4.2021
EU/1/20/1510	Oyavas	Norway	8.4.2021
EU/1/20/1495	Palforzia	Iceland	18.1.2021
EU/1/20/1495	Palforzia	Liechtenstein	28.2.2021
EU/1/20/1495	Palforzia	Norway	15.1.2021
EU/1/21/1535	Pemazyre	Iceland	30.3.2021
EU/1/21/1535	Pemazyre	Liechtenstein	30.4.2021
EU/1/21/1535	Pemazyre	Norway	8.4.2021
EU/1/20/1487	Phelinun	Liechtenstein	28.2.2021
EU/1/20/1497	Phesgo	Iceland	11.1.2021
EU/1/20/1497	Phesgo	Liechtenstein	15.1.2021
EU/1/21/1550	Ponvory	Iceland	9.6.2021
EU/1/21/1550	Ponvory	Liechtenstein	30.6.2021
EU/1/21/1550	Ponvory	Norway	4.6.2021
EU/2/20/254	Prevexxion RN	Liechtenstein	28.2.2021
EU/2/20/255	Prevexxion RN+HVT+IBD	Norway	4.1.2021
EU/2/17/211	Prevomax	Liechtenstein	28.2.2021
EU/1/20/1482	Rekambys	Iceland	11.1.2021
EU/1/20/1482	Rekambys	Liechtenstein	15.1.2021
EU/1/20/1482	Rekambys	Norway	5.1.2021
EU/1/20/1527	Retsevmo	Iceland	19.2.2021
EU/1/20/1527	Retsevmo	Liechtenstein	28.2.2021
EU/1/20/1527	Retsevmo	Norway	11.2.2021
EU/2/20/263	Rexxolide	Iceland	4.1.2021
EU/2/20/263	Rexxolide	Liechtenstein	28.2.2021
EU/1/19/1400	Rhokiinsa	Liechtenstein	28.2.2021
EU/1/20/1488	Rivaroxaban Accord	Liechtenstein	15.1.2021

EU-Number	Product	Country	Date of authorisation
EU/1/20/1502	Roclanda	Iceland	12.1.2021
EU/1/20/1502	Roclanda	Liechtenstein	28.2.2021
EU/1/20/1502	Roclanda	Norway	14.1.2021
EU/1/20/1460	Rozlytrek	Liechtenstein	28.2.2021
EU/1/20/1518	Rukobia	Iceland	19.2.2021
EU/1/20/1518	Rukobia	Liechtenstein	28.2.2021
EU/1/20/1518	Rukobia	Norway	11.2.2021
EU/1/20/1431	Ruxience	Liechtenstein	28.2.2021
EU/1/20/1435	Sarclisa	Liechtenstein	28.2.2021
EU/1/21/1533	Seffalair Spiromax	Iceland	14.4.2021
EU/1/21/1533	Seffalair Spiromax	Liechtenstein	30.4.2021
EU/1/21/1533	Seffalair Spiromax	Norway	8.4.2021
EU/1/20/1517	Sibnayal	Iceland	14.5.2021
EU/1/20/1517	Sibnayal	Liechtenstein	30.6.2021
EU/1/20/1517	Sibnayal	Norway	5.5.2021
EU/1/20/1501	Sogroya	Iceland	15.4.2021
EU/1/20/1501	Sogroya	Liechtenstein	30.4.2021
EU/1/20/1501	Sogroya	Norway	8.4.2021
EU/2/20/269	Solensia	Liechtenstein	28.2.2021
EU/2/20/269	Solensia	Norway	14.6.2021
EU/1/19/1421	Staquis	Liechtenstein	28.2.2021
EU/1/20/1511	Sunitinib Accord	Iceland	4.3.2021
EU/1/20/1511	Sunitinib Accord	Liechtenstein	30.4.2021
EU/1/20/1511	Sunitinib Accord	Norway	5.3.2021
EU/1/20/1484	Supemtek	Liechtenstein	15.1.2021
EU2/09/099	Suvaxyn PCV	Liechtenstein	28.2.2021
EU/2/18/231	Syvazul BTV	Liechtenstein	28.2.2021
EU/1/20/1492	Tecartus	Iceland	8.1.2021
EU/1/20/1492	Tecartus (conditional)	Liechtenstein	15.1.2021
EU/1/19/1378	Temybric Ellipta	Liechtenstein	28.2.2021
EU/1/21/1536	Thiotepa Riemser	Iceland	15.4.2021
EU/1/21/1536	Thiotepa Riemser	Liechtenstein	30.4.2021
EU/1/21/1536	Thiotepa Riemser	Norway	8.4.2021

EU-Number	Product	Country	Date of authorisation
EU/1/18/1351	Trecondi	Liechtenstein	15.1.2021
EU/1/19/1419	Trepulmix	Liechtenstein	28.2.2021
EU/1/20/1498	Trixeo Aerosphere	Iceland	8.1.2021
EU/1/20/1498	Trixeo Aerosphere	Liechtenstein	28.2.2021
EU/1/20/1526	Tukysa	Iceland	19.2.2021
EU/1/20/1526	Tukysa	Liechtenstein	28.2.2021
EU/1/20/1526	Tukysa	Norway	25.2.2021
EU/2/20/257	Tulinovet	Liechtenstein	15.1.2021
EU/2/20/252	Tulissin	Liechtenstein	28.2.2021
EU/2/21/272	Ultifend ND IBD	Iceland	12.5.2021
EU/2/21/272	Ultifend ND IBD	Liechtenstein	30.4.2021
EU/2/21/272	Ultifend ND IBD	Norway	29.4.2021
EU/1/20/1524	Vazkepa	Iceland	30.3.2021
EU/1/20/1524	Vazkepa	Liechtenstein	30.4.2021
EU/1/20/1524	Vazkepa	Norway	8.4.2021
EU/2/20/266	Vectormune FP ILT	Iceland	5.1.2021
EU/2/20/266	Vectormune FP ILT	Liechtenstein	15.1.2021
EU/2/20/266	Vectormune FP ILT	Norway	4.1.2021
EU/1/18/1298	Veyvondi	Liechtenstein	28.2.2021
EU/1/20/1481	Vocabria	Iceland	26.1.2021
EU/1/20/1481	Vocabria	Liechtenstein	28.2.2021
EU/1/20/1500	Xofluza	Iceland	12.1.2021
EU/1/20/1500	Xofluza	Liechtenstein	28.2.2021
EU/1/20/1500	Xofluza	Norway	14.1.2021
EU/1/20/1513	Yuflyma	Iceland	24.2.2021
EU/1/20/1513	Yuflyma	Liechtenstein	28.2.2021
EU/1/20/1513	Yuflyma	Norway	25.2.2021
EU/2/17/210	Zeleris	Liechtenstein	28.2.2021
EU/2/09/186	Zulvac 8 Bovis	Liechtenstein	28.2.2021
EU/2/17/207	Zulvac BTV Ovis	Liechtenstein	28.2.2021
EU/1/20/1478	Zynrelef	Liechtenstein	15.1.2021

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January – 30 June 2021:

EU-Number	Product	Country	Date of authorisation
EU/1/12/794	ADCETRIS	Liechtenstein	15.1.2021
EU/1/16/1098	Alprolix	Iceland	25.2.2021
EU/1/16/1098	Alprolix	Liechtenstein	30.4.2021
EU/1/16/1098	Alprolix	Norway	23.3.2021
EU/1/16/1092	Amlodipine/Valsartan Mylan	Iceland	25.1.2021
EU/1/16/1092	Amlodipine/Valsartan Mylan	Liechtenstein	28.2.2021
EU/1/15/1045	Aripiprazole Accord	Liechtenstein	15.1.2021
EU/1/16/1091	Atazanavir Mylan	Iceland	17.5.2021
EU/1/16/1091	Atazanavir Mylan	Liechtenstein	30.4.2021
EU/1/16/1091	Atazanavir Mylan	Norway	3.5.2021
EU/1/15/1074	Benepali	Liechtenstein	15.1.2021
EU/1/20/1474	Blenrep	Liechtenstein	30.6.2021
EU/1/16/1114	Bortezomib Hospira	Iceland	17.5.2021
EU/1/16/1114	Bortezomib Hospira	Liechtenstein	30.6.2021
EU/1/16/1114	Bortezomib Hospira	Norway	7.5.2021
EU/1/16/1102	Bortezomib SUN	Liechtenstein	30.6.2021
EU/1/16/1102	Bortezomib SUN	Norway	30.6.2021
EU/1/13/818	Bosulif	Iceland	22.2.2021
EU/1/13/818	Bosulif	Norway	8.3.2021
EU/1/13/818	Bosulif	Liechtenstein	28.2.2021
EU/1/15/1073	Briviact	Liechtenstein	15.1.2021
EU/1/16/1136	Cabometyx	Iceland	12.5.2021
EU/1/16/1136	Cabometyx	Liechtenstein	30.4.2021
EU/1/16/1136	Cabometyx	Norway	3.5.2021
EU/1/11/749	Caprelsa	Iceland	15.1.2021
EU/1/11/749	Caprelsa	Norway	3.2.2021
EU/1/11/749	Caprelsa	Liechtenstein	28.2.2021

EU-Number	Product	Country	Date of authorisation
EU/1/15/1055	Ciambra	Liechtenstein	28.2.2021
EU/1/15/1054	Cinacalcet Mylan	Liechtenstein	15.1.2021
EU/1/16/1125	Cinqaero	Iceland	10.6.2021
EU/1/16/1125	Cinqaero	Liechtenstein	30.6.2021
EU/1/16/1125	Cinqaero	Norway	10.6.2021
EU/1/16/1087	Coagadex	Iceland	14.4.2021
EU/1/16/1087	Coagadex	Liechtenstein	30.4.2021
EU/1/16/1087	Coagadex	Norway	7.4.2021
EU/1/13/890	Cometriq	Iceland	11.3.2021
EU/1/13/890	Cometriq	Liechtenstein	28.2.2021
EU/1/17/1262	Crysvita	Iceland	2.2.2021
EU/1/17/1262	Crysvita	Liechtenstein	28.2.2021
EU/1/17/1262	Crysvita	Norway	2.2.2021
EU/1/13/875	Deltyba	Iceland	26.4.2021
EU/1/13/875	Deltyba	Liechtenstein	30.4.2021
EU/1/16/1099	Descovy	Iceland	10.3.2021
EU/1/16/1099	Descovy	Liechtenstein	28.2.2021
EU/1/16/1099	Descovy	Norway	15.3.2021
EU/1/15/1051	Ebymect	Liechtenstein	28.2.2021
EU/1/15/1052	Edistride	Liechtenstein	28.2.2021
EU/1/11/691	Eliquis	Iceland	19.1.2021
EU/1/11/691	Eliquis	Liechtenstein	28.2.2021
EU/1/11/691	Eliquis	Norway	18.1.2021
EU/1/15/1046	Elocta	Norway	22.2.2021
EU/1/16/1088	Empliciti	Iceland	13.1.2021
EU/1/16/1088	Empliciti	Liechtenstein	15.1.2021
EU/1/16/1105	EndolucinBeta	Iceland	18.2.2021
EU/1/16/1105	EndolucinBeta	Liechtenstein	28.2.2021
EU/1/16/1105	EndolucinBeta	Norway	16.2.2021
EU/1/16/1116	Epclusa	Iceland	25.3.2021
EU/1/16/1116	Epclusa	Liechtenstein	30.4.2021
EU/1/16/1116	Epclusa	Norway	25.3.2021
EU/1/15/1069	Episalvan	Liechtenstein	15.1.2021

EU-Number	Product	Country	Date of authorisation
EU/1/15/1065	Eptifibatid Accord	Liechtenstein	15.1.2021
EU/1/19/1392	Ervebo	Norway	3.2.2021
EU/1/19/1392	Ervebo-Ebola Zaire-Impfstoff	Liechtenstein	15.1.2021
EU/2/16/194	Evalon	Iceland	24.2.2021
EU/2/16/194	Evalon	Liechtenstein	28.2.2021
EU/2/16/194	Evalon	Norway	26.2.2021
EU/1/15/1075	Feraccru	Liechtenstein	15.1.2021
EU/1/16/1106	Flixabi	Iceland	10.3.2021
EU/1/16/1106	Flixabi	Liechtenstein	30.4.2021
EU/1/16/1106	Flixabi	Norway	7.4.2021
EU/1/15/1082	Galafold	Iceland	25.2.2021
EU/1/15/1082	Galafold	Liechtenstein	28.2.2021
EU/1/15/1082	Galafold	Norway	23.2.2021
EU/1/15/1061	Genvoya	Liechtenstein	28.2.2021
EU/1/11/677	Gilenya	Liechtenstein	15.1.2021
EU/1/15/1008	Hetlioz	Liechtenstein	28.2.2021
EU/1/14/987	Holoclar	Iceland	25.1.2021
EU/1/14/987	Holoclar	Liechtenstein	28.2.2021
EU/1/16/1095	Idelvion	Iceland	18.2.2021
EU/1/16/1095	Idelvion	Liechtenstein	28.2.2021
EU/1/16/1095	Idelvion	Norway	11.2.2021
EU/1/15/1064	Imlygic	Liechtenstein	15.1.2021
EU/2/15/193	Imrestor	Liechtenstein	15.1.2021
EU/1/11/676	Jevtana	Iceland	8.1.2021
EU/1/11/676	Jevtana	Liechtenstein	15.1.2021
EU/1/16/1128	Kisplyx	Liechtenstein	30.6.2021
EU/1/16/1128	Kisplyx	Norway	22.6.2021
EU/1/15/1076	Kovaltry	Liechtenstein	15.1.2021
EU/2/16/195	Letifend	Iceland	24.2.2021
EU/2/16/195	Letifend	Liechtenstein	28.2.2021
EU/2/16/195	Letifend	Norway	5.3.2021
EU/1/19/1376	Libtayo	Liechtenstein	30.6.2021
EU/1/19/1376	Libtayo	Iceland	21.5.2021

EU-Number	Product	Country	Date of authorisation
EU/1/19/1376	Libtayo	Norway	21.5.2021
EU/1/16/1096	Lonsurf	Iceland	8.1.2021
EU/1/16/1096	Lonsurf	Liechtenstein	15.1.2021
EU/1/16/1096	Lonsurf	Norway	8.1.2021
EU/1/15/1067	Lopinavir/Ritonavir Mylan	Liechtenstein	15.1.2021
EU/1/19/1355	Lorviqua	Iceland	26.4.2021
EU/1/19/1355	Lorviqua	Liechtenstein	30.4.2021
EU/1/19/1355	Lorviqua	Norway	8.4.2021
EU/1/15/1078	Natpar	Iceland	27.4.2021
EU/1/15/1078	Natpar	Liechtenstein	30.4.2021
EU/1/15/1078	Natpar	Norway	26.4.2021
EU/1/15/1053	Neofordex	Iceland	15.1.2021
EU/1/15/1053	Neofordex	Liechtenstein	15.1.2021
EU/1/15/1053	Neofordex	Norway	31.1.2021
EU/1/16/1103	Neparvis	Iceland	22.2.2021
EU/1/16/1103	Neparvis	Liechtenstein	28.2.2021
EU/1/16/1103	Neparvis	Norway	16.2.2021
EU/1/16/1094	Ninlaro	Liechtenstein	15.1.2021
EU/1/16/1094	Ninlaro	Norway	22.2.2021
EU/1/16/1124	Nordimet	Liechtenstein	30.6.2021
EU/1/16/1124	Nordimet	Norway	25.6.2021
EU/1/15/1035	Obizur	Liechtenstein	28.2.2021
EU/1/16/1139	Ocaliva	Iceland	25.1.2021
EU/1/16/1139	Ocaliva	Norway	3.2.2021
EU/1/16/1139	Ocaliva	Liechtenstein	28.2.2021
EU/1/16/1112	Odefsey	Iceland	19.1.2021
EU/1/16/1112	Odefsey	Liechtenstein	28.2.2021
EU/1/16/1112	Odefsey	Norway	14.1.2021
EU/1/15/1070	Oncaspar	Liechtenstein	15.1.2021
EU/1/18/1345	Ondexxya	Iceland	2.3.2021
EU/1/18/1345	Ondexxya	Liechtenstein	28.2.2021
EU/1/18/1345	Ondexxya	Norway	8.3.2021

EU-Number	Product	Country	Date of authorisation
EU/1/15/1066	Ongentys	Iceland	15.3.2021
EU/1/15/1066	Ongentys	Liechtenstein	28.2.2021
EU/1/15/1066	Ongentys	Norway	15.3.2021
EU/1/15/1059	Orkambi	Liechtenstein	15.1.2021
EU/1/16/1104	Palonosetron Accord	Iceland	22.2.2021
EU/1/16/1104	Palonosetron Accord	Liechtenstein	28.2.2021
EU/1/16/1104	Palonosetron Accord	Norway	26.2.2021
EU/1/16/1089	Pandemic influenza vaccine H5N1 AstraZeneca	Iceland	16.3.2021
EU/1/16/1089	Pandemic influenza vaccine H5N1 AstraZeneca	Liechtenstein	30.4.2021
EU/1/16/1089	Pandemic influenza vaccine H5N1 AstraZeneca	Norway	24.3.2021
EU/1/15/1071	Pemetrexed Accord	Liechtenstein	28.2.2021
EU/1/16/1115	Pemetrexed Fresenius Kabi	Iceland	12.5.2021
EU/1/16/1115	Pemetrexed Fresenius Kabi	Liechtenstein	30.4.2021
EU/1/16/1115	Pemetrexed Fresenius Kabi	Norway	20.5.2021
EU/1/15/1057	Pemetrexed Hospira	Liechtenstein	28.2.2021
EU/1/19/1388	Polivy	Iceland	5.1.2021
EU/1/19/1388	Polivy	Liechtenstein	15.1.2021
EU/1/16/1108	Qtern	Iceland	9.6.2021
EU/1/16/1108	Qtern	Liechtenstein	30.4.2021
EU/1/16/1108	Qtern	Norway	3.6.2021
EU/1/16/1090	Rasagiline Mylan	Liechtenstein	15.1.2021
EU/1/20/1460	Rozlytrek	Liechtenstein	30.6.2021
EU/1/17/1250	Rubraca	Iceland	15.3.2021
EU/1/17/1250	Rubraca	Liechtenstein	30.4.2021
EU/1/17/1250	Rubraca	Norway	11.3.2021
EU/2/16/196	Sevohale	Iceland	14.5.2021

EU-Number	Product	Country	Date of authorisation
EU/2/16/196	Sevohale	Liechtenstein	30.4.2021
EU/2/16/196	Sevohale	Norway	7.5.2021
EU/1/16/1135	Sialanar	Liechtenstein	30.6.2021
EU/1/16/1135	Sialanar	Norway	30.6.2021
EU/1/13/901	Sirturo	Iceland	14.1.2021
EU/1/13/901	Sirturo	Liechtenstein	28.2.2021
EU/1/13/901	Sirturo	Norway	8.2.2021
EU/1/15/1072	Spectrila	Liechtenstein	15.1.2021
EU/1/16/1097	Strimvelis	Iceland	14.5.2021
EU/1/16/1097	Strimvelis	Liechtenstein	30.6.2021
EU/1/16/1097	Strimvelis	Norway	7.5.2021
EU/1/15/1085	Taltz	Iceland	29.1.2021
EU/1/15/1085	Taltz	Liechtenstein	15.1.2021
EU/1/15/1085	Taltz	Norway	14.1.2021
EU/1/13/902	Translarna	Liechtenstein	28.2.2021
EU/1/15/1083	Uptravi	Iceland	8.1.2021
EU/1/15/1083	Uptravi	Liechtenstein	15.1.2021
EU/1/15/1079	Vaxelis	Liechtenstein	15.1.2021
EU/2/15/188	Vectormune ND	Iceland	18.2.2021
EU/2/15/188	Vectormune ND	Liechtenstein	28.2.2021
EU/1/20/1459	Veklury	Liechtenstein	30.6.2021
EU/1/15/1068	Wakix	Iceland	29.1.2021
EU/1/15/1068	Wakix	Liechtenstein	28.2.2021
EU/1/19/1360	Waylivra	Iceland	18.2.2021
EU/1/19/1360	Waylivra	Norway	1.3.2021
EU/1/19/1360	Waylivra	Liechtenstein	28.2.2021
EU/1/15/1042	Zalviso	Liechtenstein	15.1.2021
EU/1/16/1109	Zavicefta	Iceland	24.2.2021
EU/1/16/1109	Zavicefta	Liechtenstein	28.2.2021
EU/1/16/1109	Zavicefta	Norway	26.2.2021
EU/1/16/1119	Zepatier	Iceland	14.5.2021

EU-Number	Product	Country	Date of authorisation
EU/1/16/1119	Zepatier	Liechtenstein	30.6.2021
EU/1/16/1119	Zepatier	Norway	18.5.2021
EU/1/11/690	Zoely	Iceland	25.5.2021
EU/1/11/690	Zoely	Liechtenstein	30.6.2021
EU/1/11/690	Zoely	Norway	31.5.2021
EU/1/20/1443	Zolgensma	Iceland	8.6.2021
EU/1/20/1443	Zolgensma	Liechtenstein	30.6.2021
EU/1/20/1443	Zolgensma	Norway	2.6.2021
EU/1/16/1093	Zonisamide Mylan	Iceland	4.1.2021
EU/1/16/1093	Zonisamide Mylan	Liechtenstein	28.2.2021

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January – 30 June 2021:

EU-Number	Product	Country	Date of authorisation
EU/1/13/838/006	Aubagio	Norway	22.6.2021
EU/1/18/1336/009	Buvidal	Iceland	16.6.2021
EU/1/18/1336/009	Buvidal	Norway	3.6.2021
EU/1/06/367/013	Diacomit	Iceland	10.6.2021
EU/1/06/367/013	Diacomit	Norway	10.6.2021
EU/2/11/128/004-010	Emdocam	Iceland	25.5.2021
EU/1/18/1319/009-010	Hulio	Iceland	18.1.2021
EU/1/18/1319/009-010	Hulio	Norway	18.1.2021
EU/1/20/1447/006-007	Insulin Aspart Sanofi	Iceland	14.5.2021
EU/1/20/1447/006-007	Insulin Aspart Sanofi	Norway	4.5.2021
EU/1/19/1364/002	Nuceiva	Iceland	29.1.2021
EU/1/19/1364/002	Nuceiva	Norway	27.1.2021
EU/1/14/934/007-008	Plegridy	Iceland	8.1.2021
EU/1/08/442/025-031	Pradaxa	Iceland	21.1.2021
EU/1/08/442/025-031	Pradaxa	Norway	19.1.2021
EU/1/13/901/003	Sirturo	Iceland	15.4.2021
EU/1/13/901/003	Sirturo	Norway	8.4.2021
EU/1/19/1361/002-003	Skyrizi	Iceland	10.6.2021
EU/1/19/1361/002-003	Skyrizi	Norway	4.6.2021
EU/1/10/622/003	Tepadina	Iceland	15.4.2021
EU/1/10/622/003	Tepadina	Norway	19.4.2021
EU/1/13/892/007	Tivicay	Iceland	25.1.2021
EU/1/13/892/007	Tivicay	Norway	18.1.2021
EU/1/17/1208/006-009	Trimbow	Iceland	29.1.2021
EU/1/17/1208/010-012	Trimbow	Iceland	26.4.2021
EU/1/17/1208/006-009	Trimbow	Norway	26.1.2021
EU/1/17/1208/010-012	Trimbow	Norway	12.4.2021
EU/1/06/346/002	Tysabri	Iceland	15.4.2021

EU-Number	Product	Country	Date of authorisation
EU/1/06/346/002	Tysabri	Norway	8.4.2021
EU/1/08/472/050-051	Xarelto	Iceland	1.2.2021
EU/1/17/472/050-051	Xarelto	Norway	26.1.2021
EU/1/18/1312/003-004	Xerava	Iceland	2.3.2021
EU/1/18/1312/003-004	Xerava	Norway	5.3.2021

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January – 30 June 2021:

EU-Number	Product	Country	Date of withdrawal
EU/2/08/088	Acticam	Iceland	26.3.2021
EU/2/08/088	Acticam	Liechtenstein	30.4.2021
EU/2/08/088	Acticam	Norway	26.3.2021
EU/1/16/1122	Aerivio Spiromax	Liechtenstein	28.2.2021
EU/1/16/1123	Airexar Spiromax	Liechtenstein	28.2.2021
EU/1/18/1269	Alpivab	Liechtenstein	15.1.2021
EU/1/07/390	Altargo	Liechtenstein	28.2.2021
EU/1/10/625	Arzerra	Liechtenstein	28.2.2021
EU/1/06/355	ATryn	Liechtenstein	28.2.2021
EU/1/19/1382	Azacitidin Celgene	Liechtenstein	30.6.2021
EU/1/19/1382	Azacitidine Celgene	Iceland	25.5.2021
EU/1/19/1382	Azacitidine Celgene	Norway	16.6.2021
EU/1/15/1081	Caspofungin Accord	Iceland	25.2.2021
EU/1/15/1081	Caspofungin Accord	Liechtenstein	28.2.2021
EU/1/10/623	Clopidogrel/Acetylsalicylic acid Zentiva	Liechtenstein	28.2.2021
EU/1/10/623	Clopidogrel/Acetylsalicylic acid Zentiva	Norway	1.3.2021
EU/1/96/024	Crixivan	Iceland	14.4.2021
EU/1/96/024	Crixivan	Liechtenstein	30.4.2021
EU/1/96/024	Crixivan	Norway	16.6.2021
EU/1/17/1240	Cyltezo	Liechtenstein	28.2.2021
EU/1/01/187	DepoCyte	Liechtenstein	28.2.2021
EU/1/18/1300	Duzallo	Liechtenstein	28.2.2021
EU/1/13/908	Eperzan	Liechtenstein	28.2.2021
EU/1/09/510	Fertavid	Liechtenstein	28.2.2021
EU/1/18/1288	Halimatoz	Iceland	12.1.2021
EU/1/18/1288	Halimatoz	Liechtenstein	28.2.2021

EU-Number	Product	Country	Date of withdrawal
EU/1/18/1288	Halimatoz	Norway	9.2.2021
EU/1/00/144	Helixate NexGen	Liechtenstein	28.2.2021
EU/1/13/876	Imatinib Medac	Liechtenstein	28.2.2021
EU/1/17/1243	Imatinib Teva B.V.	Liechtenstein	28.2.2021
EU/1/08/505	Intanza	Liechtenstein	28.2.2021
EU/1/01/191	Ketek	Liechtenstein	28.2.2021
EU/1/13/895	Kolbam	Liechtenstein	28.2.2021
EU/1/20/1516	Lextemy	Liechtenstein	30.6.2021
EU/1/16/1162	Lusduna	Liechtenstein	28.2.2021
EU/1/05/325	Macugen	Liechtenstein	28.2.2021
EU/1/04/297	Nodetrip (tidl.Xeristar)	Liechtenstein	30.6.2021
EU/1/04/297	Nodetrip (tidl.Xeristar)	Norway	16.6.2021
EU/1/01/186	Nonafact	Liechtenstein	28.2.2021
EU/1/15/1044	Numient	Liechtenstein	28.2.2021
EU/1/14/924	Olysio	Liechtenstein	28.2.2021
EU/1/04/287	Osseor	Liechtenstein	28.2.2021
EU/1/00/131	PegIntron	Iceland	17.5.2021
EU/1/00/131	PegIntron	Liechtenstein	30.4.2021
EU/1/00/131	PegIntron	Norway	6.5.2021
EU/1/15/1084	Portrazza	Iceland	2.3.2021
EU/1/15/1084	Portrazza	Liechtenstein	28.2.2021
EU/1/08/453	Prepandrix	Iceland	14.1.2021
EU/1/08/453	Prepandrix	Liechtenstein	28.2.2021
EU/1/08/453	Prepandrix	Norway	9.2.2021
EU/1/04/288	Protelos	Liechtenstein	28.2.2021
EU/1/20/1463	Qutavina	Liechtenstein	15.1.2021
EU/1/10/634	Ribavirin Mylan	Liechtenstein	28.2.2021
EU/1/07/388	Sebivo	Liechtenstein	15.1.2021
EU/1/06/358	Silgard	Liechtenstein	28.2.2021
EU/1/16/1163	Solymbic	Liechtenstein	28.2.2021
EU/1/15/1017	Taxespira	Liechtenstein	28.2.2021
EU/1/09/610	Telmisartan Teva	Iceland	9.6.2021
EU/1/09/610	Telmisartan Teva	Liechtenstein	30.6.2021

EU-Number	Product	Country	Date of withdrawal
EU/1/09/610	Telmisartan Teva	Norway	16.6.2021
EU/1/09/552	Topotecan Teva	Liechtenstein	28.2.2021
EU/1/16/1126	Truberzi	Iceland	12.1.2021
EU/1/16/1126	Truberzi	Liechtenstein	15.1.2021
EU/1/16/1126	Truberzi	Norway	3.2.2021
EU/1/18/1303	Udenyca	Iceland	18.2.2021
EU/1/18/1303	Udenyca	Liechtenstein	28.2.2021
EU/1/18/1303	Udenyca	Norway	15.2.2021
EU/1/17/1180	Varuby	Liechtenstein	28.2.2021
EU/1/12/752	Vepacel	Liechtenstein	15.1.2021
EU/1/11/705	Vibativ	Liechtenstein	28.2.2021
EU/1/11/704	Victrelis	Liechtenstein	28.2.2021
EU/1/00/132	ViraferonPeg	Iceland	19.1.2021
EU/1/00/132	ViraferonPeg	Liechtenstein	28.2.2021
EU/1/00/132	ViraferonPeg	Norway	29.1.2021
EU/1/11/671	Xiapex	Liechtenstein	28.2.2021
EU/1/16/1121	Zalmoxis	Liechtenstein	28.2.2021

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January – 30 June 2021:

EU-Number	Product	Country	Date of suspension

Dangerous substances – List of authorisation decisions taken by the EEA EFTA States in accordance with Article 44(5) of Regulation (EU) 528/2012 in the first half of 2021

(2022/C 29/05)

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 225/2013 of 13 December 2013, the EEA Joint Committee is invited to note the following lists concerning authorisation decisions adopted on the basis of Article 44(5) of Regulation (EU) No 528/2012 for the period 1 January – 30 June 2021, at their meeting on 24 September 2021.

ANNEX

List of authorisation decisions

The following authorisation decisions in accordance with Article 44(5) of Regulation (EU) No 528/2012) have been taken in the EEA EFTA States during the period 1 January – 30 June 2021:

Biocidal Product Name	Union authorisation decisions under Article 44(5) of Regulation (EU) No 528/2012	Country	Date of decision
Aero-Sense Aircraft Insecticide ASD	32021R0368	Iceland	23.4.2021
Aero-Sense Aircraft Insecticide ASD	32021R0368	Liechtenstein	15.4.2021
Aero-Sense Aircraft Insecticide ASD	32021R0368	Norway	22.4.2021
Contec Hydrogen Peroxide	32020D2124	Norway	15.4.2021
DEC-AHOL® Product Family	32021R0552	Iceland	25.6.2021
DEC-AHOL® Product Family	32021R0552	Liechtenstein	17.6.2021
DEC-AHOL® Product Family	32021R0552	Norway	15.6.2021
Iodine Teat Dip Products	32020R0202	Iceland	19.5.2021
Iodine Teat Dip Products	32020R0202	Liechtenstein	18.5.2021
Iodine Teat Dip Products	32020R0202	Norway	20.5.2021
Perform-IPA	32020R1991	Iceland	23.4.2021
Perform-IPA	32020R1991	Liechtenstein	15.4.2021
Perform-IPA	32020R1991	Norway	13.4.2021
PeridoxRTU	32020R1425	Iceland	19.4.2021
PeridoxRTU	32020R1425	Liechtenstein	29.3.2021
PeridoxRTU	32020R1425	Norway	13.4.2021

Dangerous substances – List of authorisation decisions taken by the EEA EFTA States in accordance with Article 64(8) of Regulation (EC) 1907/2006 (REACH) in the first half of 2021

(2022/C 29/06)

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 25/2008 of 14 March 2008, the EEA Joint Committee is invited to note the following lists concerning authorisation decisions adopted on the basis of Article 64(8) of Regulation (EC) No 1907/2006 (REACH) for the period 1 January – 30 June 2021, at their meeting on 24 September 2021.

ANNEX

List of authorisation decisions

The following authorisation decisions in accordance with Article 64(8) of Regulation (EC) 1907/2006 (REACH) have been taken in the EEA EFTA States during the period 1 January – 30 June 2021:

Substance name	Commission decision under Article 64(8) of Regulation (EC) No 1907/2006	Country	Date of decision
Chromium trioxide	C(2020) 8735	Iceland	10.2.2021
Chromium trioxide	C(2020) 8735	Liechtenstein	14.1.2021
Chromium trioxide	C(2020) 8735	Norway	11.1.2021
Chromium trioxide	C(2020) 8798	Iceland	10.2.2021
Chromium trioxide	C(2020) 8798	Liechtenstein	14.1.2021
Chromium trioxide	C(2020) 8798	Norway	11.1.2021
Chromium trioxide	C(2020) 8797	Iceland	10.2.2021
Chromium trioxide	C(2020) 8797	Liechtenstein	14.1.2021
Chromium trioxide	C(2020) 8797	Norway	11.1.2021
Chromium trioxide	C(2020) 7104	Liechtenstein	3.2.2021
Pitch, coal tar, high-temp. ('CTPht')	C(2021) 47	Iceland	4.3.2021
Pitch, coal tar, high-temp. ('CTPht')	C(2021) 47	Liechtenstein	27.1. 2021
Pitch, coal tar, high-temp. ('CTPht')	C(2021) 47	Norway	8.2.2021
Trichloroethylene (TCE)	C(2021) 1385	Iceland	7.4.2021
Trichloroethylene (TCE)	C(2021) 1385	Liechtenstein	23.3.2021
Trichloroethylene (TCE)	C(2021) 1385	Norway	23.3.2021

V

(Announcements)

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMMON COMMERCIAL POLICY

EUROPEAN COMMISSION

Notice of initiation of an expiry review of the anti-dumping measures applicable to imports of certain aluminium road wheels originating in the People's Republic of China

(2022/C 29/07)

Following the publication of a Notice of impending expiry ([1]) of the anti-dumping measures in force on the imports of certain aluminium road wheels originating in the People's Republic of China ('the country concerned'), the European Commission ('the Commission') has received a request for review pursuant to Article 11(2) of Regulation (EU) 2016/1036 of the European Parliament and of the Council of 8 June 2016 on protection against dumped imports from countries not members of the European Union ([2]) ('the basic Regulation').

1. Request for review

The request was submitted on 21 October 2021 by the Association of European Wheel Manufacturers ('the applicant') on behalf of the Union industry of certain aluminium road wheels in the sense of Article 5(4) of the basic Regulation.

An open version of the request and the analysis of the degree of support by Union producers for the request are available in the file for inspection by interested parties. Section 5.6 of this Notice provides information about access to the file for interested parties.

2. Product under review

The product subject to this review is aluminium road wheels of the motor vehicles of headings 8701 to 8705, whether or not with their accessories and whether or not fitted with tyres ('the product under review'), currently falling within CN codes ex 8708 70 10 and ex 8708 70 50 (TARIC codes: 8708 70 10 15, 8708 70 10 50, 8708 70 50 15 and 8708 70 50 50). The CN and TARIC codes are given for information only.

3. Existing measures

The measures currently in force are a definitive anti-dumping duty imposed by Commission Implementing Regulation (EU) No 2017/109 ([3]).

4. Grounds for the review

The request is based on the grounds that the expiry of the measures would be likely to result in continuation of dumping and continuation or recurrence of injury to the Union industry.

([1]) OJ C 161, 3.5.2021, p.2.
([2]) OJ L 176, 30.6.2016, p. 21.
([3]) Commission Implementing Regulation (EU) 2017/109 of 23 January 2017 imposing a definitive anti-dumping duty on imports of certain aluminium road wheels originating in the People's Republic of China following an expiry review pursuant to Article 11(2) of Regulation (EU) 2016/1036 of the European Parliament and of the Council (OJ L 18, 24.1.2017, p. 1).

4.1. ***Allegation of likelihood of continuation of dumping***

The applicant claimed that it is not appropriate to use domestic prices and costs in the country concerned, due to the existence of significant distortions within the meaning of point (b) of Article 2(6a) of the basic Regulation.

To substantiate the allegations of significant distortions, the applicant relied on the information contained in the country report produced by the Commission services on 20 December 2017 describing the specific market circumstances in the country concerned ([4]). In particular, the applicant referred to distortions as state presence in general and more specific affecting the aluminium sector. In addition, the applicant relied on publicly available information, in particular on the report 'Overcapacity in China: An impediment to the Party's Reform Agenda' issued by the EU Chamber of Commerce in Beijing ([5]) and the OECD report 'Measuring distortions in international markets - The aluminium value chain' ([6]). According to the OECD report, non-market forces, and government support in particular, appear to explain increased overcapacity in the aluminium industry in the country concerned. This overcapacity and the consequences thereof are also identified in the report issued by the EU Chamber of Commerce in Beijing. Finally, the applicant also relied on the Commission's findings in several recent anti-dumping investigations concerning the aluminium sector ([7]) ([8]) ([9]).

As a result, in view of Article 2(6a)(a) of the basic Regulation, the allegation of continuation of dumping from the country concerned is based on a comparison of a constructed normal value on the basis of costs of production and sale reflecting undistorted prices or benchmarks in an appropriate representative country with the export price (at ex- works level) of the product under review from the country concerned when sold for export to the Union.

On this basis the dumping margins calculated are significant for the country concerned.

In light of the information available, the Commission considers that there is sufficient evidence pursuant to Article 5(9) of the basic Regulation tending to show that, due to significant distortions affecting prices and costs, the use of domestic prices and costs in the country concerned is inappropriate, thus warranting the initiation of an investigation on the basis of Article 2(6a) of the basic Regulation.

The country report is available in the file for inspection by interested parties and on DG Trade's website ([10]).

4.2. ***Allegation of likelihood of continuation or recurrence of injury***

The applicant alleges the likelihood of continuation or recurrence of injury. In this respect the applicant has provided sufficient evidence that imports of the product under review from the country concerned to the Union have remained significant in absolute terms and in terms of market shares.

The applicant has also provided evidence that, should measures be allowed to lapse, the current import level of the product under review from the country concerned to the Union is likely to increase due to the existence of unused capacity of the manufacturing facilities of the producers in the country concerned and the attractiveness of the Union market. In addition, in the absence of measures, Chinese export prices would be at a level low enough to injure the Union industry. The applicant finally alleges that any substantial increase of imports at dumped prices from the country concerned would be likely to cause further injury to the Union industry should measures be allowed to lapse.

([4]) Commission Staff Working Document, on Significant Distortions in the Economy of the People's Republic of China for the Purposes of Trade Defence Investigations, 20 December 2017, SWD(2017) 483 final/2, available at: https://trade.ec.europa.eu/doclib/docs/2017/december/tradoc_156474.pdf

([5]) https://www.europeanchamber.com.cn/en/publications-overcapacity-in-china

([6]) https://www.oecd-ilibrary.org/trade/measuring-distortions-in-international-markets-the-aluminium-value-chain_c82911ab-en

([7]) Commission implementing Regulation (EU) 2019/915 of 4 June 2019 imposing a definitive anti-dumping duty on imports of certain aluminium foil in rolls originating in the People's Republic of China following an expiry review under Article 11(2) of Regulation (EU) 2016/1036 of the European Parliament and of the Council (OJ L 146, 5.6.2019, p. 63).

([8]) Commission implementing Regulation (EU) 2021/546 of 29 March 2021 imposing a definitive anti-dumping duty and definitively collecting the provisional duty imposed on imports of aluminium extrusions originating in the People's Republic of China (OJ L109, 30.3.2021, p. 1).

([9]) Commission implementing Regulation (EU) 2021/582 of 9 April 2021 imposing a provisional anti-dumping duty on imports of aluminium flat-rolled products originating in the People's Republic of China (OJ L 124, 12.4.2021, p. 40).

([10]) Documents cited in the country report may also be obtained upon a duly reasoned request.

5. **Procedure**

Having determined, after consulting the Committee established by Article 15(1) of the basic Regulation, that sufficient evidence of a likelihood of dumping and injury exists to justify the initiation of an expiry review, the Commission hereby initiates a review in accordance with Article 11(2) of the basic Regulation.

The expiry review will determine whether the expiry of the measures would be likely to lead to a continuation or recurrence of dumping of the product under review originating in the country concerned and a continuation or recurrence of injury to the Union industry.

The Commission also draws the attention of the parties to the published Notice ([11]) on the consequences of the COVID-19 outbreak on anti-dumping and anti-subsidy investigations that may be applicable to this proceeding.

5.1. ***Review investigation period and period considered***

The investigation of a continuation or recurrence of dumping will cover the period from 1 October 2020 to 30 September 2021 ('the review investigation period'). The examination of trends relevant for the assessment of the likelihood of a continuation or recurrence of injury will cover the period from 1 January 2018 to the end of the investigation period ('the period considered').

5.2. ***Comments on the request and the initiation of the investigation***

All interested parties wishing to comment on the request (including matters pertaining to continuation or recurrence of injury and causality) or any aspects regarding the initiation of the investigation (including the degree of support for the request) must do so within 37 days of the date of publication of this Notice in the *Official Journal of the European Union* ([12]).

Any request for a hearing with regard to the initiation of the investigation must be submitted within 15 days of the date of publication of this Notice.

5.3. ***Procedure for the determination of a likelihood of continuation or recurrence of dumping***

In an expiry review, the Commission examines exports that were made to the Union in the review investigation period and, irrespective of exports to the Union, considers whether the situation of the companies producing and selling the product under review in the country concerned is such that exports at dumped prices to the Union would be likely to continue or recur if measures expire.

Therefore, all producers ([13]) of the product under review from the country concerned, including those that did not cooperate in the investigation leading to the measures in force, are invited to participate in the Commission investigation.

5.3.1. *Investigating producers in the country concerned*

In view of the potentially large number of producers in the country concerned involved in this expiry review and in order to complete the investigation within the statutory time limits, the Commission may limit the producers to be investigated to a reasonable number by selecting a sample (this process is also referred to as 'sampling'). The sampling will be carried out in accordance with Article 17 of the basic Regulation.

In order to enable the Commission to decide whether sampling is necessary, and if so, to select a sample, all producers, or representatives acting on their behalf, including the ones who did not cooperate in the investigation leading to the measures subject to the present review, are hereby requested to provide the Commission with information on their companies within 7 days of the date of publication of this Notice. This information must be provided via TRON.tdi at the following address: https://tron.trade.ec.europa.eu/tron/tdi/form/R759_SAMPLING_FORM_FOR_EXPORTING_PRODUCER. Tron access information can be found in sections 5.6 and 5.9 below.

([11]) https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A52020XC0316%2802%29

([12]) All references to the publication of this Notice will be references to publication of this Notice in the *Official Journal of the European Union*, unless otherwise specified.

([13]) A producer is any company in the country concerned which produces the product under review, including any of its related companies involved in the production, domestic sales or exports of the product under review.

In order to obtain the information it deems necessary for the selection of the sample of producers, the Commission will also contact the authorities the country concerned and may contact any known associations of producers in the country concerned.

If a sample is necessary, the producers will be selected based on the largest representative volume of production, sales or exports which can reasonably be investigated within the time available. All known producers in the country concerned, the authorities of the country concerned and associations of producers will be notified by the Commission, via the authorities of the country concerned if appropriate, of the companies selected to be in the sample.

Once the Commission has received the necessary information to select a sample of producers, it will inform the parties concerned of its decision whether they are included in the sample. The sampled producers will have to submit a completed questionnaire within 30 days from the date of notification of the decision of their inclusion in the sample, unless otherwise specified.

The Commission will add a note to the file for inspection by interested parties reflecting the sample selection. Any comment on the sample selection must be received within 3 days of the date of notification of the sample decision.

A copy of the questionnaire for producers in the country concerned is available in the file for inspection by interested parties and on DG Trade's Internet: https://trade.ec.europa.eu/tdi/case_details.cfm?id=2575.

Without prejudice to the possible application of Article 18 of the basic Regulation, companies that have agreed to their possible inclusion in the sample but are not selected to be in the sample will be considered to be cooperating.

5.3.2. *Additional procedure with regard to the country concerned that is subject to significant distortions*

Subject to the provisions of this Notice, all interested parties are hereby invited to make their views known, submit information and provide supporting evidence regarding the application of Article 2(6a) of the basic Regulation. Unless otherwise specified, this information and supporting evidence must reach the Commission within 37 days of the date of publication of this Notice.

In particular, the Commission invites all interested parties to make their views known on the inputs and the Harmonised System (HS) codes provided in the request, propose (an) appropriate representative country(ies) and provide the identity of producers of the product under investigation in those countries. This information and supporting evidence must reach the Commission within 15 days of the date of publication of this Notice.

Pursuant to point (e) of Article 2(6a) of the basic Regulation, the Commission will, shortly after initiation, by means of a note to the file for inspection by interested parties, inform parties to the investigation about the relevant sources that it intends to use for the purpose of determining normal value in the country concerned pursuant to Article 2(6a) of the basic Regulation. This will cover all sources, including the selection of an appropriate representative third country where appropriate. Parties to the investigation shall be given 10 days from the date at which that note is added to that file to submit comments.

According to the information available to the Commission, a possible representative third country for the country concerned in this case is Brazil. With the aim of finally selecting the appropriate representative third country, the Commission will examine whether there are countries with a similar level of economic development as the country concerned, in which there is production and sales of the product under review and in which relevant data are readily available. Where there is more than one such country, preference will be given, where appropriate, to countries with an adequate level of social and environmental protection.

With regard to the relevant sources, the Commission invites all producers in the country concerned to provide information on the materials (raw and processed) and energy used in the production of the product under review within 15 days of the date of publication of this Notice. This information must be provided via TRON.tdi at the following address: https://tron.trade.ec.europa.eu/tron/tdi/form/R759_INFO_ON_INPUTS_FOR_EXPORTING_PRODUCER_FORM. Tron access information can be found in sections 5.6 and 5.9 below.

Furthermore, any submissions of factual information to value costs and prices pursuant to point (a) of Article 2(6a) of the basic Regulation must be filed within 65 days of the date of publication of this Notice. Such factual information should be taken exclusively from publicly available sources.

In order to obtain the information it deems necessary for its investigation with regard to the alleged significant distortions within the meaning of point (b) of Article 2(6a) of the basic Regulation, the Commission will also make available a questionnaire to the Government of the country concerned.

5.3.3. *Investigating unrelated importers* ([14]) ([15])

Unrelated importers of the product under review from the country concerned to the Union, including those that did not cooperate in the investigation leading to the measures in force, are invited to participate in this investigation.

In view of the potentially large number of unrelated importers involved in this expiry review and in order to complete the investigation within the statutory time limits, the Commission may limit to a reasonable number the unrelated importers that will be investigated by selecting a sample (this process is also referred to as 'sampling'). The sampling will be carried out in accordance with Article 17 of the basic Regulation.

In order to enable the Commission to decide whether sampling is necessary and, if so, to select a sample, all unrelated importers, or representatives acting on their behalf, including the ones who did not cooperate in the investigation leading to the measures subject to the present review, are hereby requested to make themselves known to the Commission. These parties must do so within 7 days of the date of publication of this Notice by providing the Commission with the information on their company(ies) requested in Annex to this Notice.

In order to obtain information it deems necessary for the selection of the sample of unrelated importers, the Commission may also contact any known associations of importers.

If a sample is necessary, the importers may be selected based on the largest representative volume of sales of the product under review from the country concerned in the Union that can reasonably be investigated within the time available. All known unrelated importers and associations of importers will be notified by the Commission of the companies selected to be in the sample.

The Commission will also add a note to the file for inspection by interested parties reflecting the sample selection. Any comment on the sample selection must be received within 3 days of the date of notification of the sample decision.

In order to obtain the information it deems necessary for its investigation, the Commission will make available questionnaires to the sampled unrelated importers. Those parties must submit a completed questionnaire within 30 days from the date of the notification of the sample selection, unless otherwise specified.

([14]) Only importers not related to producers in the country(ies) concerned can be sampled. Importers that are related to producers have to fill in Annex I to the questionnaire for these producers. In accordance with Article 127 of Commission Implementing Regulation (EU) 2015/2447 of 24 November 2015 laying down detailed rules for implementing certain provisions of Regulation (EU) No 952/2013 of the European Parliament and of the Council laying down the Union Customs Code, two persons shall be deemed to be related if: (a) they are officers or directors of the other person's business; (b) they are legally recognised partners in business; (c) they are employer and employee; (d) a third party directly or indirectly owns, controls or holds 5 % or more of the outstanding voting stock or shares of both of them; (e) one of them directly or indirectly controls the other; (f) both of them are directly or indirectly controlled by a third person; (g) together they control a third person directly or indirectly; or (h) they are members of the same family (OJ L 343, 29.12.2015, p. 558). Persons shall be deemed to be members of the same family only if they stand in any of the following relationships to one another: (i) husband and wife, (ii) parent and child, (iii) brother and sister (whether by whole or half blood), (iv) grandparent and grandchild, (v) uncle or aunt and nephew or niece, (vi) parent-in-law and son-in-law or daughter-in-law, (vii) brother-in-law and sister-in-law. In accordance with Article 5(4) of Regulation (EU) No 952/2013 of the European Parliament and of the Council laying down the Union Customs Code, "person" means a natural person, a legal person, and any association of persons which is not a legal person but which is recognised under Union or national law as having the capacity to perform legal acts (OJ L 269, 10.10.2013, p. 1).

([15]) The data provided by unrelated importers may also be used in relation to aspects of this investigation other than the determination of dumping.

A copy of the questionnaire for unrelated importers is available in the file for inspection by interested parties and on DG Trade's Internet: https://trade.ec.europa.eu/tdi/case_details.cfm?id=2575.

5.4. ***Procedure for the determination of a likelihood of a continuation or recurrence of injury***

In order to establish whether there is a likelihood of a continuation or recurrence of injury to the Union industry, the Commission invites Union producers of the product under review to participate in the investigation.

5.4.1. *Investigating Union producers*

In view of the large number of Union producers involved in this expiry review and in order to complete the investigation within the statutory time limits, the Commission has decided to limit to a reasonable number the Union producers that will be investigated by selecting a sample (this process is also referred to as 'sampling'). The sampling is carried out in accordance with Article 17 of the basic Regulation.

The Commission has provisionally selected a sample of Union producers. Details can be found in the file for inspection by interested parties.

Interested parties are hereby invited to comment on the provisional sample. In addition, other Union producers, or representatives acting on their behalf, including Union producers who did not cooperate in the investigation leading to the measures in force, that consider that there are reasons why they should be included in the sample must contact the Commission within 7 days of the date of publication of this Notice. All comments regarding the provisional sample must be received within 7 days of the date of publication of this Notice, unless otherwise specified.

The Commission will notify all known Union producers and/or associations of Union producers of the companies finally selected to be in the sample.

The sampled Union producers will have to submit a completed questionnaire within 30 days from the date of notification of the decision of their inclusion in the sample, unless otherwise specified.

A copy of the questionnaire for Union producers is available in the file for inspection by interested parties and on DG Trade's Internet: https://trade.ec.europa.eu/tdi/case_details.cfm?id=2575.

5.5. ***Procedure for the assessment of Union interest***

Should the likelihood of continuation or recurrence of dumping and injury be confirmed, a decision will be reached, pursuant to Article 21 of the basic Regulation, as to whether maintaining the anti-dumping measures would not be against the Union interest.

Union producers, importers and their representative associations, users and their representative associations, trade unions and representative consumer organisations are invited to provide the Commission with information on the Union interest.

Information concerning the assessment of the Union interest must be provided within 37 days of the date of publication of this Notice, unless otherwise specified. This information may be provided either in a free format or by completing a questionnaire prepared by the Commission.

A copy of the questionnaires, including the questionnaire for users of the product under review, is available in the file for inspection by interested parties and on DG Trade's Internet: https://trade.ec.europa.eu/tdi/case_details.cfm?id=2575. In any case, information submitted pursuant to Article 21 will only be taken into account if supported by factual evidence at the time of submission, which substantiates its validity.

5.6. ***Interested parties***

In order to participate in the investigation, interested parties, such as producers in the country concerned, Union producers, importers and their representative associations, users and their representative associations, trade unions and representative consumer organisations first have to demonstrate that there is an objective link between their activities and the product under review.

Producers in the country concerned, Union producers, importers and representative associations who made information available in accordance to the procedures described in sections 5.3.1, 5.3.3 and 5.4.1 will be considered as interested parties if there is an objective link between their activities and the product under review.

Other parties will only be able to participate in the investigation as interested party from the moment they make themselves known, and provided that there is an objective link between their activities and the product under review. Being considered as an interested party is without prejudice to the application of Article 18 of the basic Regulation.

Access to the file available for inspection for interested parties is made via Tron.tdi at the following address: https://tron.trade.ec.europa.eu/tron/TDI. Please follow the instructions on that page to get access ([16]).

5.7. *Other written submissions*

Subject to the provisions of this Notice, all interested parties are hereby invited to make their views known, submit information and provide supporting evidence. Unless otherwise specified, this information and supporting evidence must reach the Commission within 37 days of the date of publication of this Notice.

5.8. *Possibility to be heard by the Commission investigation services*

All interested parties may request to be heard by the Commission investigation services. Any request to be heard must be made in writing and must specify the reasons for the request as well as a summary of what the interested party wishes to discuss during the hearing. The hearing will be limited to the issues set out by the interested parties in writing beforehand.

In principle, hearings will not be used to present factual information which is not yet on file. Nevertheless, in the interest of good administration and to enable Commission services to progress with the investigation, interested parties may be directed to provide new factual information after a hearing.

5.9. *Instructions for making written submissions and sending completed questionnaires and correspondence*

Information submitted to the Commission for the purpose of trade defence investigations shall be free from copyrights. Interested parties, before submitting to the Commission information and/or data which is subject to third party copyrights, must request specific permission to the copyright holder explicitly allowing the Commission a) to use the information and data for the purpose of this trade defence proceeding and b) to provide the information and/or data to interested parties to this investigation in a form that allows them to exercise their rights of defence.

All written submissions, including the information requested in this Notice, completed questionnaires and correspondence provided by interested parties for which confidential treatment is requested shall be labelled 'Sensitive' ([17]). Parties submitting information in the course of this investigation are invited to reason their request for confidential treatment.

Interested parties providing 'Sensitive' information are required to furnish non-confidential summaries of it pursuant to Article 19(2) of the basic Regulation, which will be labelled 'For inspection by interested parties'. These summaries must be sufficiently detailed to permit a reasonable understanding of the substance of the information submitted in confidence. If a party providing confidential information fails to show good cause for a confidential treatment request or does not furnish a non-confidential summary of it in the requested format and quality, the Commission may disregard such information unless it can be satisfactorily demonstrated from appropriate sources that the information is correct.

([16]) In case of technical problems please contact the Trade Service Desk by Email: trade-service-desk@ec.europa.eu or by Tel. +32 22979797.

([17]) A 'Sensitive' document is a document which is considered confidential pursuant to Article 19 of the basic Regulation and Article 6 of the WTO Agreement on Implementation of Article VI of the GATT 1994 (Anti-Dumping Agreement). It is also a document protected pursuant to Article 4 of Regulation (EC) No 1049/2001 of the European Parliament and of the Council (OJ L 145, 31.5.2001, p. 43).

Interested parties are invited to make all submissions and requests via TRON.tdi (https://tron.trade.ec.europa.eu/ tron/TDI) including scanned powers of attorney and certification sheets. By using TRON.tdi or email, interested parties express their agreement with the rules applicable to electronic submissions contained in the document 'CORRESPONDENCE WITH THE EUROPEAN COMMISSION IN TRADE DEFENCE CASES' published on the website of the Directorate-General for Trade: http://trade.ec.europa.eu/doclib/docs/2011/june/tradoc_148003.pdf. The interested parties must indicate their name, address, telephone and a valid email address and they should ensure that the provided email address is a functioning official business email which is checked on a daily basis. Once contact details are provided, the Commission will communicate with interested parties by TRON.tdi or email only, unless they explicitly request to receive all documents from the Commission by another means of communication or unless the nature of the document to be sent requires the use of a registered mail. For further rules and information concerning correspondence with the Commission including principles that apply to submissions via TRON.tdi and by email, interested parties should consult the communication instructions with interested parties referred to above.

Commission address for correspondence:
European Commission
Directorate-General for Trade
Directorate G
Office: CHAR 04/039
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

TRON. tdi: https://tron.trade.ec.europa.eu/tron/tdi

Email:

For dumping issues: TRADE-R759-ARW-CN-DUMPING@ec.europa.eu

For injury and Union interest issues: TRADE-R759-ARW-CN-INJURY@ec.europa.eu

6. Schedule of the investigation

The investigation shall normally be concluded within 12 months and in any event no later than 15 months from the date of the publication of this Notice, pursuant to Article 11(5) of the basic Regulation.

7. Submission of information

As a rule, interested parties may only submit information in the timeframes specified in section 5 of this Notice.

In order to complete the investigation within the mandatory deadlines, the Commission will not accept submissions from interested parties after the deadline to provide comments on the final disclosure or, if applicable, after the deadline to provide comments on the additional final disclosure.

8. Possibility to comment on other parties' submissions

In order to guarantee the rights of defence, interested parties should have the possibility to comment on information submitted by other interested parties. When doing so, interested parties may only address issues raised in the other interested parties' submissions and may not raise new issues.

Comments on the information provided by other interested parties in reaction to the disclosure of the definitive findings should be submitted within 5 days from the deadline to comment on the definitive findings, unless otherwise specified. If there is an additional final disclosure, comments on the information provided by other interested parties in reaction to this further disclosure should be made within 1 day from the deadline to comment on this further disclosure, unless otherwise specified.

The outlined timeframe is without prejudice to the Commission's right to request additional information from interested parties in duly justified cases.

9. Extension to time limits specified in this Notice

Extensions to time-limits provided for in this Notice may be granted upon request of interested parties showing due cause.

Any extension to the time limits provided for in this Notice should only be requested in exceptional circumstances and will only be granted if duly justified. In any event, any extensions to the deadline to reply to questionnaires will be limited normally to 3 days, and as a rule will not exceed 7 days. Regarding time limits for the submission of other information specified in the Notice of initiation, extensions will be limited to 3 days unless exceptional circumstances are demonstrated.

10. **Non-cooperation**

In cases where any interested party refuses access to or does not provide the necessary information within the time limits, or significantly impedes the investigation, findings, affirmative or negative, may be made on the basis of facts available, in accordance with Article 18 of the basic Regulation.

Where it is found that any interested party has supplied false or misleading information, the information may be disregarded and use may be made of facts available.

If an interested party does not cooperate or cooperates only partially and findings are therefore based on facts available in accordance with Article 18 of the basic Regulation, the result may be less favourable to that party than if it had cooperated.

Failure to give a computerised response shall not be deemed to constitute non-cooperation, provided that the interested party shows that presenting the response as requested would result in an unreasonable extra burden or unreasonable additional cost. The interested party should immediately contact the Commission.

11. **Hearing Officer**

Interested parties may request the intervention of the Hearing Officer in trade proceedings. The Hearing Officer reviews requests for access to the file, disputes regarding the confidentiality of documents, requests for extension of time limits and any other request concerning the rights of defence of interested parties and third parties as may arise during the proceeding.

The Hearing Officer may organise hearings and mediate between the interested party/-ies and Commissions services to ensure that the interested parties' rights of defence are being fully exercised. A request for a hearing with the Hearing Officer should be made in writing and should specify the reasons for the request. The Hearing Officer will examine the reasons for the requests. These hearings should only take place if the issues have not been settled with the Commission services in due course.

Any request must be submitted in good time and expeditiously so as not to jeopardise the orderly conduct of proceedings. To that effect, interested parties should request the intervention of the Hearing Officer at the earliest possible time following the occurrence of the event justifying such intervention. Where hearing requests are submitted outside the relevant timeframes, the Hearing Officer will also examine the reasons for such late requests, the nature of the issues raised and the impact of those issues on the rights of defence, having due regard to the interests of good administration and the timely completion of the investigation.

For further information and contact details interested parties may consult the Hearing Officer's web pages on DG Trade's Internet: http://ec.europa.eu/trade/trade-policy-and-you/contacts/hearing-officer/.

12. **Possibility to request a review under Article 11(3) of the basic Regulation**

As this expiry review is initiated in accordance with the provisions of Article 11(2) of the basic Regulation, the findings thereof will not lead to the existing measures being amended but will lead to those measures being repealed or maintained in accordance with Article 11(6) of the basic Regulation.

If any interested party considers that a review of the measures is warranted so as to allow for the possibility to amend the measures, that party may request a review pursuant to Article 11(3) of the basic Regulation.

Parties wishing to request such a review, which would be carried out independently of the expiry review mentioned in this Notice, may contact the Commission at the address given above.

13. **Processing of personal data**

Any personal data collected in this investigation will be treated in accordance with Regulation (EU) 2018/1725 of the European Parliament and of the Council ([18]).

A data protection notice that informs all individuals of the processing of personal data in the framework of Commission's trade defence activities is available on DG Trade's Internet: http://ec.europa.eu/trade/policy/accessing-markets/trade-defence/

([18]) Regulation (EU) 2018/1725 of the European Parliament and of the Council of 23 October 2018 on the protection of natural persons with regard to the processing of personal data by the Union institutions, bodies, offices and agencies and on the free movement of such data, and repealing Regulation (EC) No 45/2001 and Decision No 1247/2002/EC (OJ L 295, 21.11.2018, p. 39).

ANNEX

☐	'Sensitive' version
☐	Version 'For inspection by interested parties'
	(tick the appropriate box)

ANTI-DUMPING PROCEEDING CONCERNING IMPORTS OF CERTAIN ALUMINIUM ROAD WHEELS ORIGINATING IN THE PEOPLE'S REPUBLIC OF CHINA

INFORMATION FOR THE SELECTION OF THE SAMPLE OF UNRELATED IMPORTERS

This form is designed to assist unrelated importers in responding to the request for sampling information made in point 5.3.3 of the notice of initiation.

Both the 'Sensitive' version and the version 'For inspection by interested parties' should be returned to the Commission as set out in the notice of initiation.

1. **IDENTITY AND CONTACT DETAILS**

Supply the following details about your company:

Company name	
Address	
Contact person	
E-mail address	
Telephone	

2. **TURNOVER AND SALES VOLUME**

Indicate the total turnover in euros (EUR) of the company, the value in euros (EUR) and volume in pieces and in tonnes for imports into the Union and resales on the Union market after importation from the People's Republic of China, during the review investigation period, of the product under review as defined in the notice of initiation.

	Volume in pieces	Volume in tonnes	Value in euros (EUR)
Total turnover of your company in euros (EUR)			
Imports of the product under review originating in the People's Republic of China into the Union			
Imports of the product under review into the Union (all origins)			
Resales on the Union market after importation from the People's Republic of China of the product under review			

3. **ACTIVITIES OF YOUR COMPANY AND RELATED COMPANIES** ([1])

Give details of the precise activities of the company and all related companies (please list them and state the relationship to your company) involved in the production and/or selling (export and/or domestic) of the product under review. Such activities could include but are not limited to purchasing the product under review, producing it under sub-contracting arrangements, or processing or trading it.

Company name and location	Activities	Relationship

4. **OTHER INFORMATION**

Please provide any other relevant information which the company considers useful to assist the Commission in the selection of the sample.

5. **CERTIFICATION**

By providing the above information, the company agrees to its possible inclusion in the sample. If the company is selected to be part of the sample, this will involve completing a questionnaire and accepting a visit at its premises in order to verify its response. If the company indicates that it does not agree to its possible inclusion in the sample, it will be deemed not to have cooperated in the investigation. The Commission's findings for non-cooperating importers are based on the facts available and the result may be less favourable to that company than if it had cooperated.

Signature of authorised official:

Name and title of authorised official:

Date:

([1]) In accordance with Article 127 of Commission Implementing Regulation (EU) 2015/2447 of 24 November 2015 laying down detailed rules for implementing certain provisions of Regulation (EU) No 952/2013 of the European Parliament and of the Council laying down the Union Customs Code, two persons shall be deemed to be related if: (a) they are officers or directors of the other person's business; (b) they are legally recognised partners in business; (c) they are employer and employee; (d) a third party directly or indirectly owns, controls or holds 5 % or more of the outstanding voting stock or shares of both of them; (e) one of them directly or indirectly controls the other; (f) both of them are directly or indirectly controlled by a third person; (g) together they control a third person directly or indirectly; or (h) they are members of the same family (OJ L 343, 29.12.2015, p. 558). Persons shall be deemed to be members of the same family only if they stand in any of the following relationships to one another: (i) husband and wife, (ii) parent and child, (iii) brother and sister (whether by whole or half blood), (iv) grandparent and grandchild, (v) uncle or aunt and nephew or niece, (vi) parent-in-law and son-in-law or daughter-in-law, (vii) brother-in-law and sister-in-law. In accordance with Article 5(4) of Regulation (EU) No 952/2013 of the European Parliament and of the Council laying down the Union Customs Code, "person" means a natural person, a legal person, and any association of persons which is not a legal person but which is recognised under Union or national law as having the capacity to perform legal acts (OJ L 269, 10.10.2013, p. 1).

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

EUROPEAN COMMISSION

Prior notification of a concentration

(Case M.10564 – APOLLO / MISSGUIDED)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 29/08)

1. On 13 January 2022, the Commission received notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 ([1]).

This notification concerns the following undertakings:

— Alteri Investments II SC ('Alteri') (Luxembourg), controlled by Apollo Management L.P. (U.S.A.),

— Nakai Investments Limited, ('Nakai Investments') (British Virgin Islands), controlled by Mr. Rajib Passi,

— Missguided Limited ('Missguided') (United Kingdom), controlled by Mr. Rajib Passi.

Alteri and Nakai Investments acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of Missguided Limited.

The concentration is accomplished by way of purchase of shares in a newly created company constituting a joint venture.

2. The business activities of the undertakings concerned are:

— for Alteri: Alteri is a subsidiary of Apollo. Apollo manages investments in companies worldwide that are active in a variety of sectors, including oil and gas, retail, and information technology. It also controls Walz Group and CBR Group, which are *inter alia* active in the design, wholesale and retail of women's apparel.

— for Nakai Investments: Nakai Investments is a company indirectly and wholly held by Mr. Rajib Passi. Mr. Rajib Passi also controls By Design LLC, which is a wholesale clothing fashion group active in the U.S.A.

— for Missguided: Missguided is a UK-based online retailer (e-commerce) active worldwide. It is active in both the retail and wholesale supply of clothing, apparel, footwear, and 'health and beauty' products. Missguided is currently solely controlled by Mr. Rajib Passi, who owns 100 % of Missguided through R Holding Company Limited ('R Holding', British Virgin Islands) and Nakai Investments.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 ([2]) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').
([2]) OJ C 366, 14.12.2013, p. 5.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10564 – APOLLO / MISSGUIDED

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

ISSN 1977-091X (electronic edition)
ISSN 1725-2423 (paper edition)

Publications Office
of the European Union
L-2985 Luxembourg
LUXEMBOURG

EN